Esperion Therapeutics, Inc.

ESPRNASDAQHealthcare● Active

$3.14

+$0.01(+0.32%)

Market Cap$652833378

P/E Ratio—

52W High$4.18

52W Low$0.95

Avg Volume12.0M

Open$3.15

Beta1.07

Free Cash Flow Financials Revenue

Esperion Therapeutics, Inc. (ESPR) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ESPR · free cash flow · updated Jun 8, 2026

Core FCF metrics

ESPR · FCF · TTM · margin & CAGR

Free cash flow was −$13.1M for FY2025 (fiscal year ending 2025-12-31), up 45.4% year-over-year The FCF margin was -3.3%.

FY2025 Free Cash Flow−$13.1M▲ +45.4% YoY

Trailing 12M (TTM)−$18.2Mtrailing 4 quarters sum

FCF Margin-3.3%−$13.1M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ESPR · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$13.1M(0M)−$13.1M▲ +45.4%-3.3%

FY2024−$23.7M(0M)−$24.0M▲ +82.3%-7.2%

FY2023−$135.5M(0M)−$135.5M▲ +22.5%-116.5%

FY2022−$174.8M(0M)−$174.8M▲ +33.7%-231.6%

FY2021−$263.8M(0M)−$263.8M▼ 167.7%-336.3%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ESPR · P/FCF · FCF yield · FCF per share

Esperion Therapeutics, Inc. (ESPR) reported negative free cash flow of −$0.01B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

ESPR · cash flow statement · operating / investing / financing

For FY2025, Esperion Therapeutics, Inc. generated −$13.1M in operating cash flow and spent 0M in capital expenditures, yielding −$13.1M in free cash flow.

Operating Activities

−$13.1M

Cash from core business operations

2025-12-31

Investing Activities

+$0.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$36.2M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$13.1M) − |CapEx| (0M) = FCF (−$13.1M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ESPR vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Esperion Therapeutics, Inc.YOU

ESPR

−$13.1M+45.4%-3.2%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Esperion Therapeutics, Inc. (ESPR) reported free cash flow of −$13.1M for FY2025 (fiscal year ending 2025-12-31), up 45.4% year-over-year. The FCF margin was -3.3%.

Esperion Therapeutics, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 15 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ESPR free cash flow · 8 questions

Esperion Therapeutics, Inc. free cash flow was −$13.1M for FY2025, up 45.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$18.2M.

ESPR free cash flowESPR FCFESPR FCF 2025ESPR free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Esperion Therapeutics, Inc. · Esperion Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026